The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na, Kyoung-Sae | - |
dc.contributor.author | Jung, Han-Yong | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.date.accessioned | 2021-09-05T12:24:53Z | - |
dc.date.available | 2021-09-05T12:24:53Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-01-03 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99554 | - |
dc.description.abstract | Schizophrenia is a serious mental illness with chronic symptoms and significant impairment in psychosocial functioning. Although novel antipsychotics have been developed, the negative and cognitive symptoms of schizophrenia are still unresponsive to pharmacotherapy. The high level of social impairment and a chronic deteriorating course suggest that schizophrenia likely has neurodegenerative characteristics. Inflammatory markers such as pro-inflammatory cytokines are well-known etiological factors for psychiatric disorders, including schizophrenia. Inflammation in the central nervous system is closely related to neurodegeneration. In addition to pro-inflammatory cytokines, microglia also play an important role in the inflammatory process in the CNS. Uncontrolled activity of pro-inflammatory cytokines and microglia can induce schizophrenia in tandem with genetic vulnerability and glutamatergic neurotransmitters. Several studies have investigated the possible effects of antipsychotics on inflammation and neurogenesis. Additionally, anti-inflammatory adjuvant therapy has been under investigation as a treatment option for schizophrenia. Further studies should consider the confounding effects of systemic factors such as metabolic syndrome and smoking. In addition, the unique mechanisms by which pro-inflammatory cytokines are involved in the etiopathology of schizophrenia should be investigated. In this article, we aimed to review(1) major findings regarding neuroinflammation and pro-inflammatory cytokine alterations in schizophrenia, (2) interactions between neuroinflammation and neurogenesis as possible neural substrates for schizophrenia, and (3) novel pharmacological approaches. (C) 2012 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | TUMOR-NECROSIS-FACTOR | - |
dc.subject | LEUKEMIA INHIBITORY FACTOR | - |
dc.subject | BLOOD-BRAIN-BARRIER | - |
dc.subject | ADULT HIPPOCAMPAL NEUROGENESIS | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | CENTRAL-NERVOUS-SYSTEM | - |
dc.subject | INDUCED MICROGLIAL ACTIVATION | - |
dc.subject | SIGNAL-TRANSDUCTION PATHWAYS | - |
dc.subject | MATERNAL IMMUNE ACTIVATION | - |
dc.subject | ADD-ON THERAPY | - |
dc.title | The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.1016/j.pnpbp.2012.10.022 | - |
dc.identifier.scopusid | 2-s2.0-84888883580 | - |
dc.identifier.wosid | 000328074200040 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.48, pp.277 - 286 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 48 | - |
dc.citation.startPage | 277 | - |
dc.citation.endPage | 286 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | TUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | LEUKEMIA INHIBITORY FACTOR | - |
dc.subject.keywordPlus | BLOOD-BRAIN-BARRIER | - |
dc.subject.keywordPlus | ADULT HIPPOCAMPAL NEUROGENESIS | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | CENTRAL-NERVOUS-SYSTEM | - |
dc.subject.keywordPlus | INDUCED MICROGLIAL ACTIVATION | - |
dc.subject.keywordPlus | SIGNAL-TRANSDUCTION PATHWAYS | - |
dc.subject.keywordPlus | MATERNAL IMMUNE ACTIVATION | - |
dc.subject.keywordPlus | ADD-ON THERAPY | - |
dc.subject.keywordAuthor | Schizophrenia | - |
dc.subject.keywordAuthor | Cytokine | - |
dc.subject.keywordAuthor | Neuroinflammation | - |
dc.subject.keywordAuthor | Neurogenesis | - |
dc.subject.keywordAuthor | Neurodegeneration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.